Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

280
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
What are Viruses?00:50

What are Viruses?

128.2K
Overview
128.2K
Facilitated Transport01:19

Facilitated Transport

148.1K
The chemical and physical properties of plasma membranes cause them to be selectively permeable. Since plasma membranes have both hydrophobic and hydrophilic regions, substances need to be able to transverse both regions. The hydrophobic area of membranes repels substances such as charged ions. Therefore, such substances need special membrane proteins to cross a membrane successfully. In  facilitated transport, also known as facilitated diffusion, molecules and ions travel across a...
148.1K
Chromosome Replication02:31

Chromosome Replication

10.6K
Before a cell can divide, it must accurately replicate all of its chromosomes, including the DNA and its associated histone and non-histone proteins.  This process begins at numerous origins of replication during the S phase of the cell cycle in each of a cell’s chromosomes simultaneously. Certain nucleotides can act as origins of replication, but these sequences are not well defined - especially in complex, multi-cellular, eukaryotic species. The length of DNA that spans an origin...
10.6K
E2 Reaction: Stereochemistry and Regiochemistry02:43

E2 Reaction: Stereochemistry and Regiochemistry

13.6K
Elimination reactions of alkyl halides can yield one or more alkenes depending on the specific regiochemical and stereochemical considerations. While the regiochemistry of the reaction governs the location of the double bond in the product, the stereochemical requirements often influence the geometry.
When a substrate with two different β hydrogens undergoes an E2 elimination, the presence of a strong base can yield two regioisomeric alkenes. The more-substituted alkene is the major...
13.6K
E2 Reaction: Kinetics and Mechanism02:45

E2 Reaction: Kinetics and Mechanism

12.5K
SN2 substitutions and E2 eliminations of alkyl halides proceed via a concerted pathway. While the nucleophile attacks the alpha carbon in SN2 reactions, it functions as a strong base and abstracts a beta hydrogen in the E2 mechanism. The rate-limiting transition state in E2 elimination reactions is characterized by partially broken carbon–hydrogen and carbon–halogen bonds and a partially formed pi bond between the alpha and beta carbons. The beta hydrogen and halide are eliminated...
12.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TIM-3-dependent lysosome biogenesis is required for myelin debris clearance in macrophages.

Brain : a journal of neurology·2026
Same author

Tim-3 facilitates dendritic cell ferroptosis and impairs antitumor immunity in steatohepatitis-related HCC.

Journal of hepatology·2026
Same author

Impact of early enteral nutrition combined with bedside rehabilitation on functional outcomes and length of stay in patients with severe subarachnoid hemorrhage: a retrospective cohort study.

Frontiers in neurology·2026
Same author

Correction to: Gsα deficiency in macrophages promotes tumor progression via the MAPK signaling pathway.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

Gsα deficiency in macrophages promotes tumor progression via the MAPK signaling pathway.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

Differential Effects of Saturated and Unsaturated Fatty Acids on Colorectal Cancer via IDO1 Signaling.

Cancer medicine·2026

Related Experiment Video

Updated: Feb 3, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Prostaglandin E2 facilitates Hepatitis B virus replication by impairing CTL function.

Xiaoyan Li1, Tingting Xie2, Lifen Gao2

  • 1Key Laboratory for Experimental Teratology of Ministry of Education, Key Laboratory of Infection and Immunity of Shandong Province and Department of Immunology, Shandong University School of Medicine, Jinan, Shandong, 250012, China; Department of laboratory, Baoding NO.1 Central hospital, Baoding, Hebei, 071000, China.

Molecular Immunology
|October 16, 2018
PubMed
Summary

Prostaglandin E2 (PGE2) elevates in chronic Hepatitis B patients, impairing CD8+ T cell function and promoting viral persistence. Blocking PGE2 signaling restores T cell immunity, offering a potential therapeutic strategy for Hepatitis B virus (HBV) infection.

Keywords:
CD8+ T cellsChronic HBV infectionCytokine secretionCytotoxicityPGE2

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Experiment Videos

Last Updated: Feb 3, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Area of Science:

  • Immunology
  • Hepatology
  • Virology

Background:

  • T cell dysfunction reversal is a promising therapeutic strategy for chronic diseases.
  • Prostaglandin E2 (PGE2) is a key immunoregulator with potential therapeutic applications.
  • Chronic Hepatitis B virus (HBV) infection is a significant global health concern.

Purpose of the Study:

  • To investigate the role of PGE2 in T cell dysfunction and HBV persistence.
  • To explore the therapeutic potential of targeting PGE2 signaling in Chronic Hepatitis B (CHB).

Main Methods:

  • Serum PGE2 levels were measured in CHB patients and healthy donors.
  • HBV replication was assessed in an AAV-HBV mouse model and HBV-harboring hepatocyte cell lines.
  • T cell function markers (Tim-3, perforin, granzyme B) in CD8+ T cells were analyzed.
  • The effects of PGE2 analogues and receptor antagonists (EP2, EP4) were evaluated.
  • CD8+ T cell depletion was performed to assess their role in PGE2-mediated effects.

Main Results:

  • CHB patients exhibited significantly elevated serum PGE2 levels, correlating with viral load and liver damage.
  • PGE2 administration promoted HBV replication in mice, while EP2/EP4 antagonists inhibited it.
  • High PGE2 levels in CHB patients were associated with increased Tim-3 expression and reduced perforin/granzyme B in CD8+ T cells.
  • Blocking PGE2 signaling restored CD8+ T cell function and controlled HBV infection.
  • CD8+ T cells were critical for the observed effects of PGE2 on HBV replication.

Conclusions:

  • PGE2 acts as a negative regulator of CD8+ T cell function, contributing to HBV persistence.
  • Targeting PGE2 signaling pathways presents a promising therapeutic avenue for managing Chronic Hepatitis B.